ClinicalTrials.gg
RecruitingNCT05335603FALLUpdated Apr 19, 2022

An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis

An observational study in Chronic Liver Disease, sponsored by University of Copenhagen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-19.

Sponsored by University of Copenhagen · Observational

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
335
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Non-alcoholic Fatty Liver Disease with a site in Denmark — 10 open to participants now, 15 under way, 2 of them phase 3. Non-alcoholic Fatty Liver Disease · Denmark.

Planned enrollment
5th of 15
335 · median 48
Started
2020
with 3 others
Observational
15 of 46
5 open now
Primary completion
2036-08
later than 14 of 14 live
Registered
39th of 46
by date
Lead sponsor
4 of 46
University of Copenhagen

Among the 46 studies in Non-alcoholic Fatty Liver Disease with a site in Denmark, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2020, is one of 15 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 39th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

10 of the 46 studies in Non-alcoholic Fatty Liver Disease with a site in Denmark are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Non-alcoholic Fatty Liver Disease with a site in Denmark, or all of them as a file.
02

Study summary

Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.

03

Conditions studied

  • Chronic Liver Disease

Keywords

  • non-alcoholic fatty liver disease
  • non-alcoholic steatohepatitis
  • steatosis
  • autoimmune hepatitis
  • primary biliary cholangitis
  • primary sclerosing cholangitis
  • haemochromatosis
  • alfa-1-antitrypsin deficiency
  • chronic pancreatitis
  • chronic liver disease
  • inflammatory bowel disease
  • OMICS
  • Mass spectrometry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Potentially eligible patients will be identified and recruited among those referred with suspected liver disease at the outpatient clinic at the Gastro Unit, Copenhagen University Hospital Hvidovre, Denmark. Healthy control participants will be recruited through advertisements at forsoegsperson.dk and posters. Posters will be mounted in neutral places at Copenhagen University Hospital Hvidovre and at neutral places at the Panum Institute. Copenhagen University Hospital Hvidovre is a large regional hospital with more than 3500 employees and the Panum Institute is a large building complex in Copenhagen, Denmark that houses the Faculty of Health and Medical Sciences.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients/healthy control participants (age 18 or above) who can give their
  • Suspected liver disease:
  • non-alcoholic steatohepatitis
  • alcoholic steatohepatitis
  • hepatitis
  • primary biliary cholangitis
  • primary sclerosing cholangitis
  • inflammatory bowel disease
  • polycystic ovary syndrome
  • hereditary haemochromatosis
  • chronic pancreatitis
  • cystic fibrosis
  • alpha-1 antitrypsin deficiency

Exclusion criteria

Exclusion Criteria:

Patients with:

  • malignant diseases
  • viral hepatitis
  • to liver
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
335 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Identification and validation of a diagnostic classifier enabling discrimination of chronic liver diseases.

    OMICS based analyses on plasma and liver tissue

    Time frame: 10 years

Secondary outcomes

  1. To identify any metabolic disturbances within chronic liver diseases

    Collection of plasma during an oral glucose tolerance test measuring pancreatic and gut hormones

    Time frame: Plasma obtained at time point 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min.

Other outcomes

  1. Fibrosis stage of the liver

    Non-invasive scoring systems (e.g. Fibroscan, Fib-4)

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Aug 2036, 192 months after the start.

Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's planned 192 months is above that.

Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 19, 2022
StartActual
Aug 24, 2020
Primary completionEst.
Aug 2036
CompletionEst.
Aug 2036
Last update
Apr 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05335603
Responsible party
Nicolai Jacob Wewer Albrechtsen (Associate professor, University of Copenhagen) — Principal investigator
First posted
Apr 19, 2022
Start date
Aug 24, 2020
Primary completion
Aug 2036 (estimated)
Completion
Aug 2036 (estimated)
Last update
Apr 19, 2022

Study contacts

Anne-Sofie H Jensen, MD
Contact
anne-sofie.houlberg.jensen@regionh.dk
+4538621966
Lise L Gluud, Professor
Contact
lise.lotte.gluud.01@regionh.dk
+4538621964
Lise L Gluud, Professor
principal investigator · Hvidovre University Hospital
Nicolai J Wewer Albrechtsen, MD, PhD
principal investigator · NNF Center for Protein Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion